Patent ID: 7244441

Claim:
A stent or intra-luminal prosthesis comprising a MAP kinase inhibitor of formula (1), (2) or (3), wherein: formula (1) is: wherein represents a single or double bond; one Z 2 is CA or CR 8 A and the other is CR 1 , CR 1 2 , NR 6 or N wherein each R 1 , R 6 and R 8 is independently hydrogen or noninterfering substituent; A is —CO(X) j Y wherein Y is COR 2 or an isostere thereof and R 2 is hydrogen or a noninterfering substituent, X is a spacer preferably of 2–6 Å, and j is 0 or 1; Z 3 is NR 7 or O; each R 3 is independently a noninterfering substituent; n is 0–3; each of L 1 and L 2 is a linker; each R 4 is independently a noninterfering substituent; m is 0–4; Z 1 is CR 5 or N wherein R 5 is hydrogen or a noninterfering substituent; each of 1 and k is an integer from 0–2 wherein the sum of 1 and k is 0–3; Ar is an aryl group substituted with 0–5 noninterfering substituents, wherein two noninterfering substituents can form a fused ring; and the distance between the atom of Ar linked to L 2 and the center of the α ring is preferably less than 24 Å; formula (2)is: wherein; represents a single or double bond; each Z 2 is independantly CR 1 or CR 1 2 wherein R 1 is independently hydrogen or noninterfering substituent; R 7 is a non-interferring substituent; each of Z 4 and Z 5 is independently N or CR 1 is as defined above and wherein at least one of Z 4 and Z 5 is N; each R 3 is independently a noninterfering substituent; n is 0–3; each of L 1 and L 2 is a linker; each R 4 is independently a noninterfering substituent; m is 0–4; Z 1 is CR 5 or N wherein R 5 is hydrogen or a noninterfering substituent; each of 1 and k is an integer from 0–2 wherein the sum of 1 and k is 0–3; Ar′ is a cyclic group substituted with 0–5 noninterfering substituents, wherein two said noninterfering substituents can form a fused ring; and the distance between the atom of Ar′ linked to L 2 and the center of the α ring is 4.5–24 Å; 1883 and formula (3) is: wherein one Z 2 is CA and the other is CR 1 , wherein R 1 is hydrogen or a noninterfering substituent; A is W i -COX j Y wherein Y is COR 2 wherein R 2 is hydrogen or a noninterfering substituent, each of W and X is a spacer preferably of 26 Å, and each of i and j is independently 0, 1 or 2; each R 6 is independently H, or a noninterfering substituent, wherein two R 6 may optionally form a 5–7 membered ring including the nitrogen to which they are bound; each R 3 is independently a noninterfering substituent; n is 0–3; each of L 1 and L 2 is a linker; each R 4 is independently a noninterfering substituent; m is 0–4; Z 1 is CR 5 or N wherein R 5 is hydrogen or a noninterfering substituent; Ar is a phenyl or thienyl group substituted with 0 5 noninterfering substituents, wherein two noninterfering substituents can form a fused ring; and the distance between the atom of Ar linked to L 2 and the center of the α ring is preferably 4.5 to 24 Å; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof.